OBJECTIVE: Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. RESULTS: We have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching. CONCLUSIONS: We present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA.
OBJECTIVE: Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. RESULTS: We have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching. CONCLUSIONS: We present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA.
Authors: Miguel Ángel Abad; Rafael Ariza Ariza; Juan José Aznar; Enrique Batlle; Emma Beltrán; Juan de Dios Cañete; Eugenio de Miguel; Alejandro Escudero; Cristina Fernández-Carballido; Jordi Gratacós; Estíbaliz Loza; Luis Francisco Linares; Carlos Montilla; Manuel Moreno Ramos; Juan Mulero; Rubén Queiro; Enrique Raya; Carlos Rodríguez Lozano; Jesús Rodríguez Moreno; Jesús Sanz; Lucía Silva-Fernández; Juan Carlos Torre Alonso; Pedro Zarco; José Luis Fernández-Sueiro; Xavier Juanola Journal: Rheumatol Int Date: 2014-01-04 Impact factor: 2.631
Authors: Jordi Gratacós; Jesús Luelmo; Jesús Rodríguez; Jaume Notario; Teresa Navío Marco; Pablo de la Cueva; Manel Pujol Busquets; Mercè García Font; Beatriz Joven; Raquel Rivera; Jose Luis Alvarez Vega; Antonio Javier Chaves Álvarez; Ricardo Sánchez Parera; Jose Carlos Ruiz Carrascosa; Fernando José Rodríguez Martínez; José Pardo Sánchez; Carlos Feced Olmos; Conrad Pujol; Eva Galindez; Silvia Pérez Barrio; Ana Urruticoechea Arana; Mercedes Hergueta; Pablo Coto; Rubén Queiro Journal: Rheumatol Int Date: 2018-02-07 Impact factor: 2.631